

MAY 09 2000

TECH CENTER 1600/2900

detecting the expression of cell-surface gp120 on intact cells after the cells have been [treated] contacted with the agent and determining the number of cells therein, wherein the [presence or amount] number of cells expressing cell-surface gp120 is a measure of latent viral load.

8b  
DD'  
A cont

2. (Amended) A method of [claims] claim 1, [further] comprising, prior to said contacting, obtaining the resting lymphoid mononuclear cells by the steps of:

- a) obtaining a sample cell population;
- b) depleting the sample cell population of cells expressing cell-surface gp120; and
- c) depleting sample cell population of cells expressing HLA-DRU,

whereby resting lymphoid mononuclear cells are obtained.

3. (Amended) A method of claim 2, wherein the sample cells are depleted of gp120 expressing cells by the steps of:

- a) contacting sample cells with gp120-specific antibodies, [each] said antibodies conjugated to a capture moiety, under conditions effective for the antibodies to attach to gp120 on the surface of cells, thereby forming labeled-cells;
- b) contacting the labeled-cells with capture moiety-specific antibody under conditions effective for the capture moiety-specific antibody to attach to the labeled-cells, thereby forming a complex-labeled cells; and
- c) removing the complex-labeled cells, thereby depleting sample cells of gp120+ cells.

Claim 5, line 2: Change "bead" to --particle--.

DD'  
A2

6. (Amended) A method of [claims] claim 4, wherein the magnetic particles are 10-100 nm in diameter.

7. (Amended) A method of [claims] claim 5, wherein the magnetic particles are 10-100 nm in diameter